Financials OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.8604 USD -4.93% Intraday chart for OptiNose, Inc. -3.78% -33.30%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 422.7 215.6 133.2 203.2 144.9 97.26 - -
Enterprise Value (EV) 1 422.7 215.6 133.2 203.2 144.9 97.26 97.26 97.26
P/E ratio -3.51 x -2 x -1.12 x -2.13 x -4.03 x -3.31 x -8.6 x 10.8 x
Yield - - - - - - - -
Capitalization / Revenue 12.2 x 4.39 x 1.78 x 2.66 x 2.04 x 1.06 x 0.75 x 0.63 x
EV / Revenue 12.2 x 4.39 x 1.78 x 2.66 x 2.04 x 1.06 x 0.75 x 0.63 x
EV / EBITDA -4.99 x -2.51 x -2.02 x -3.67 x -6.48 x -24.3 x 7.66 x 3.01 x
EV / FCF -4.47 x -2.49 x -1.73 x - - -69.1 x 9.96 x 5.03 x
FCF Yield -22.4% -40.2% -57.9% - - -1.45% 10% 19.9%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 45,842 52,081 82,200 109,840 112,312 113,039 - -
Reference price 2 9.220 4.140 1.620 1.850 1.290 0.8604 0.8604 0.8604
Announcement Date 3/5/20 3/3/21 3/8/22 3/7/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 34.63 49.12 74.65 76.28 70.99 91.38 129.9 154.9
EBITDA 1 -84.63 -85.76 -65.8 -55.36 -22.35 -4.004 12.69 32.33
EBIT 1 -95.6 -87.22 -66.45 -55.9 -22.75 -11.79 6.172 25.07
Operating Margin -276.06% -177.57% -89.01% -73.28% -32.05% -12.9% 4.75% 16.19%
Earnings before Tax (EBT) 1 -110.1 -99.79 -82.3 -74.83 -35.48 -30.56 -14.69 11.8
Net income 1 -110.1 -99.79 -82.3 -74.83 -35.48 -30.56 -14.69 11.03
Net margin -317.79% -203.16% -110.24% -98.11% -49.99% -33.44% -11.3% 7.12%
EPS 2 -2.630 -2.070 -1.450 -0.8700 -0.3200 -0.2600 -0.1000 0.0800
Free Cash Flow 1 -94.59 -86.75 -77.1 - - -1.408 9.765 19.34
FCF margin -273.15% -176.62% -103.28% - - -1.54% 7.52% 12.49%
FCF Conversion (EBITDA) - - - - - - 76.93% 59.82%
FCF Conversion (Net income) - - - - - - - 175.34%
Dividend per Share - - - - - - - -
Announcement Date 3/5/20 3/3/21 3/8/22 3/7/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 21.83 22.51 14.76 20.58 20.08 20.86 11.85 19.45 19.82 19.86 13.03 21.47 25.41 33.63 24.5
EBITDA -12.89 -11.5 -19.28 - - -8.224 - - - - - - - - -
EBIT 1 -13.04 -11.67 -21.4 -15.34 -10.8 -8.356 -14.37 -4.172 -1.694 -2.512 -8.787 -5.4 -1.503 3.334 -3
Operating Margin -59.75% -51.84% -144.95% -74.56% -53.79% -40.07% -121.29% -21.45% -8.55% -12.65% -67.42% -25.15% -5.91% 9.91% -12.24%
Earnings before Tax (EBT) 1 -17.12 -15.62 -25.33 -19.4 -14.95 -15.15 -18.85 2.626 -9.294 -9.967 -13.36 -10.05 -6.137 -1.283 -7.7
Net income 1 -17.12 -15.62 -25.33 -19.4 -14.95 -15.15 -18.85 2.573 -9.294 -9.967 -13.36 -10.05 -6.137 -1.283 -7.7
Net margin -78.42% -69.41% -171.63% -94.24% -74.48% -72.64% -159.1% 13.23% -46.88% -50.17% -102.49% -46.83% -24.15% -3.81% -31.43%
EPS 2 -0.3200 -0.2300 -0.3100 -0.2300 -0.1800 -0.1700 -0.1700 0.0200 -0.0800 -0.0900 -0.1100 -0.0825 -0.0550 -0.0150 -0.0600
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/8/22 5/12/22 8/11/22 11/10/22 3/7/23 5/11/23 8/10/23 11/9/23 3/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -94.6 -86.8 -77.1 - - -1.41 9.77 19.3
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.56 0.55 0.17 0.06 0.33 0.41 0.41 0.41
Capex / Sales 1.61% 1.11% 0.22% 0.08% 0.46% 0.45% 0.32% 0.27%
Announcement Date 3/5/20 3/3/21 3/8/22 3/7/23 3/7/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8604 USD
Average target price
3.75 USD
Spread / Average Target
+335.84%
Consensus
  1. Stock Market
  2. Equities
  3. OPTN Stock
  4. Financials OptiNose, Inc.